These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3107495)

  • 41. Hypertrophic cardiomyopathy: long-term effects of propranolol versus verapamil in preventing sudden death in "low-risk" patients.
    Pelliccia F; Cianfrocca C; Romeo F; Reale A
    Cardiovasc Drugs Ther; 1990 Dec; 4(6):1515-8. PubMed ID: 2081144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Verapamil and propranolol: a comparison of two antihypertensive agents.
    Leonetti G; Pasotti C; Ferrari GP; Zanchetti A
    Acta Med Scand Suppl; 1984; 681():137-41. PubMed ID: 6587752
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Verapamil-induced ventricular tachycardia in hypertrophic cardiomyopathy.
    Wessel A; Seiffert P; Dettmann R; Heintzen PH
    Eur Heart J; 1987 Mar; 8(3):313-5. PubMed ID: 3582389
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of drugs upon exercise tests in coronary insuffiency.
    Oliveira JM
    Arq Bras Cardiol; 1977 Feb; 30 Suppl 1():79-81. PubMed ID: 329813
    [No Abstract]   [Full Text] [Related]  

  • 45. Changes of the degree of hypertrophy in hypertrophic obstructive cardiomyopathy under medical and surgical treatment.
    Curtius JM; Stoecker J; Loesse B; Welslau R; Scholz D
    Cardiology; 1989; 76(4):255-63. PubMed ID: 2529965
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status.
    Rosing DR; Kent KM; Maron BJ; Epstein SE
    Circulation; 1979 Dec; 60(6):1208-13. PubMed ID: 574067
    [No Abstract]   [Full Text] [Related]  

  • 47. Chronic verapamil therapy in pediatric and young adult patients with hypertrophic cardiomyopathy.
    Spicer RL; Rocchini AP; Crowley DC; Rosenthal A
    Am J Cardiol; 1984 Jun; 53(11):1614-9. PubMed ID: 6539561
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration.
    Pollick C
    Am J Cardiol; 1988 Dec; 62(17):1252-5. PubMed ID: 3057852
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of verapamil and propranolol on exercise tolerance in hypertensive patients.
    Mooy J; van Baak M; Böhm R; Does R; Petri H; van Kemenade J; Rahn KH
    Clin Pharmacol Ther; 1987 May; 41(5):490-5. PubMed ID: 3552358
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Verapamil and beta blockader: a hazardous therapeutic combination].
    Denis B; Pellet J; Machecourt J; Martin-Noël P
    Nouv Presse Med; 1977 Jun; 6(23):2075. PubMed ID: 887409
    [No Abstract]   [Full Text] [Related]  

  • 51. Hypertrophic cardiomyopathy--therapy with slow channel inhibiting agents.
    Chatterjee K; Raff G; Anderson D; Parmley WW
    Prog Cardiovasc Dis; 1982; 25(3):193-210. PubMed ID: 6216500
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Calcium infusion for reversal of adverse effects of intravenous verapamil.
    Morris DL; Goldschlager N
    JAMA; 1983 Jun; 249(23):3212-3. PubMed ID: 6682905
    [No Abstract]   [Full Text] [Related]  

  • 53. Verapamil: a cause of sudden death in a patient with hypertrophic cardiomyopathy.
    Perrot B; Danchin N; Terrier de la Chaise A
    Br Heart J; 1984 Mar; 51(3):352-4. PubMed ID: 6538092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of hypertrophic obstructive cardiomyopathy with verapamil.
    Kaltenbach M; Hopf R; Kober G; Bussmann WD; Keller M; Petersen Y
    Br Heart J; 1979 Jul; 42(1):35-42. PubMed ID: 573129
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration.
    Rosing DR; Condit JR; Maron BJ; Kent KM; Leon MB; Bonow RO; Lipson LC; Epstein SE
    Am J Cardiol; 1981 Sep; 48(3):545-53. PubMed ID: 7196690
    [No Abstract]   [Full Text] [Related]  

  • 56. [Evaluation of the effects of propranolol on hypertrophic cardiomyopathy by non-invasive technics].
    Fang WH; Hu ZX; Wang SH; Li JR; Liu YS
    Zhonghua Xin Xue Guan Bing Za Zhi; 1980 Mar; 8(1):13-5. PubMed ID: 7192621
    [No Abstract]   [Full Text] [Related]  

  • 57. Evolution of the electrocardiographic changes in patients with hypertrophic cardiomyopathy.
    Tendera M; Poloński L; Wodniecki J; Kardaszewicz P
    Clin Cardiol; 1991 Nov; 14(11):891-6. PubMed ID: 1764825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response.
    Cubeddu LX; Aranda J; Singh B; Klein M; Brachfeld J; Freis E; Roman J; Eades T
    JAMA; 1986 Oct 24-31; 256(16):2214-21. PubMed ID: 3531560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term medical management of hypertrophic cardiomyopathy: usefulness of propranolol.
    Frank MJ; Abdulla AM; Watkins LO; Prisant L; Stefadouros MA
    Eur Heart J; 1983 Nov; 4 Suppl F():155-64. PubMed ID: 6686531
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Syncope induced by propranolol in hypertrophic cardiomyopathy.
    García-Rubira JC; Pavón M; Romero-Chacón D
    Int J Cardiol; 1991 Jun; 31(3):358-61. PubMed ID: 1879988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.